Re: Final results of an EORTC-GU cancers group randomized study of maintenance bacillus calmette-guérin in intermediate- and high-risk ta, T1 papillary carcinoma of the urinary bladder: One-third dose versus full dose and 1 year versus 3 years of maintenance

摘要

To my knowledge, European Organization for Research and Treatment of Cancer 30962 represents one of the largest therapeutic clinical trials ever conducted in bladder cancer. The trial took place between 1997 and 2005, randomizing 1805 patients with non-muscle-invasive bladder cancer to one of four bacillus Calmette-Guerin (BCG) treatment schedules in a 2 x 2 factorial design (Table 1). The primary outcome was 5-yr disease-free survival (DFS). Median follow-up was 7.1 yr, and 43% had disease recurrence, 8% progressed to muscle invasion, and 27% of patients died (5% due to bladder cancer).